A logo

Agilent Technologies

A · What the business does, what can go wrong, and how options sellers approach it

What it does

Agilent Technologies makes the instruments, consumables, software and services that scientists use to measure and analyze chemical and biological samples. Its products include liquid and gas chromatography systems, mass spectrometers, lab software, and diagnostic tools used in areas such as cancer testing.

The company was spun out of Hewlett-Packard in 1999. Today it serves drug developers, chemical and materials makers, clinical labs, environmental and food testing groups, forensics, and academic and government researchers.

How it makes money

Agilent earns revenue in three main ways: selling instruments, selling recurring consumables (columns, reagents and supplies), and providing services and software, such as maintenance contracts and lab informatics.

Instruments are bought less often and depend on customer budgets. Consumables and services tend to be steadier because labs need them as long as their instruments are running. That mix of one-time and repeat revenue shapes how the business behaves through economic cycles.

Why investors own it

  • Exposure to biopharma, chemicals and diagnostics, where testing is a core part of the workflow.
  • A large installed base of instruments that creates ongoing demand for consumables and service.
  • Switching costs: labs build validated methods around specific equipment, so changing vendors is a hassle.
  • Geographic diversity, with the US and China among its largest markets.

Agilent is a member of the S&P 500, so it appears in many index-based portfolios.

What can go wrong

  • Drug developers and labs can delay equipment purchases when budgets tighten or funding dries up.
  • Government and academic funding can change with politics.
  • China exposure brings economic and trade-policy risk.
  • Competition from large rivals in life science tools can pressure pricing and market share.
  • Currency swings can affect reported results, since sales happen in many countries.
  • Acquisitions may not deliver what was expected.

What to watch

  • Organic revenue growth, which strips out currency and acquisitions
  • Order trends and instrument demand
  • Consumables and services growth
  • Pharma and biotech spending
  • Operating margin
  • China demand and trade policy
  • Management guidance at earnings

Options income angle

Options on A are generally available across many strikes and expirations, and the most active contracts tend to be liquid. Activity is usually lighter than in the largest mega-cap names, so check bid-ask spreads before trading.

Implied volatility usually rises ahead of quarterly earnings and when sector sentiment shifts, such as changes in pharma spending or China demand.

One caution for premium sellers: life science tools stocks can gap sharply on earnings or guidance changes. A covered call can cap gains in a big rally, and a short put can lead to owning shares after a steep drop.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended October 31, 2025, filed December 22, 2025. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

Agilent's net revenue of $6,948 million in 2025 rose 7 percent, with growth in all three segments, but margins fell as tariffs, shipping costs and a less profitable business mix weighed on results. Management says it expects to substantially mitigate the tariff impact during fiscal year 2026. It also expects higher income taxes that year and says customers funded by the U.S. federal government have not yet seen their capital spending normalize.

How the business did

  • Net revenue of $6,948 million compared with $6,510 million in 2024, which had fallen 5 percent. The BIOVECTRA acquisition contributed approximately 2 percentage points. Net income was $1,303 million versus $1,289 million, helped by several tax benefits. The effective tax rate was 9.2 percent.
  • Life Sciences and Diagnostics Markets rose 11 percent to $2,726 million, led by pharmaceutical customers and the contract development and manufacturing (CDMO) business. Agilent CrossLab rose 6 percent to $2,908 million. Applied Markets rose 1 percent to $1,314 million. Academic and government revenue declined in the first and third of these.
  • Total gross margin fell to 52.4 % from 54.3 %, and operating margin fell to 21.3 % from 22.9 %. Management cited higher tariffs and shipping costs, unfavorable mix (including lower margin in the specialty CDMO business), and higher wages and variable pay.
  • Operating cash flow was $1,559 million versus $1,751 million. Cash and cash equivalents ended at $1,789 million. The company paid $282 million in dividends and repurchased 3.4 million shares for $425 million.

Risks specific to this company

  • Tariffs and trade: Agilent sources components and manufactures in several countries. The filing names U.S. and Chinese tariff policy as a risk, and says tariff changes raised costs of revenue beginning in the second half of fiscal year 2025.
  • U.S. government funding: federal agencies are operating under a continuing resolution set to expire on January 30, 2026. Product sales to customers funded by the U.S. federal government could be affected without further appropriations.
  • Singapore tax benefits: the Singapore tax holiday decreased income taxes by $102 million in 2025 and was extended through 2030. The incentives depend on meeting investment and employment thresholds, and taxes could rise if they are lost.
  • Earthquake exposure: production facilities, headquarters and laboratories in California, and production facilities in Japan, sit in areas with above-average seismic activity. The company says it carries no insurance or financial reserves for earthquakes or terrorism, and manufacturing consolidation means little redundant capacity.
  • Debt: Agilent had approximately $3.4 billion in outstanding indebtedness, including $3.3 billion in unsecured senior notes. The credit facility has financial-ratio covenants, and the $300 million 2026 senior notes were reclassified to short-term debt.
  • Offshore back office: most accounting and tax processes are centralized in India and Malaysia. Disruption there could affect supplier payments, collections and the timing of financial reporting.

What management is watching

  • Tariff mitigation: management is pursuing supply chain optimization, targeted pricing actions and other cost-efficiency initiatives to protect margins.
  • Capital spending: anticipated fiscal year 2026 capital expenditures are approximately $500 million, mainly to expand manufacturing capacity for nucleic acid based therapeutics in Frederick, Colorado.
  • Taxes: management expects income taxes to increase in fiscal year 2026 due to top-up taxes under Pillar Two (a 15 percent global minimum tax) and the U.S. One Big Beautiful Bill Act rules.
  • Cost programs: the FY25 restructuring plan is expected to be substantially complete by the second quarter of fiscal year 2026. It is estimated to cut approximately $75 million to $80 million in annual cost of sales and operating expenses.
  • Customer demand and capital return: management says many customers' ability to spend capital budgets has begun to normalize. Remaining repurchase authorization is approximately $1.9 billion, and a quarterly dividend of $0.255 per share was declared on November 19, 2025.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended July 31, 2026, filed September 1, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

Agilent reported net revenue of $1,878 million for the quarter, up 8 percent, with growth in all three segments. Net income was $362 million, compared with $336 million a year earlier. A net benefit from tariff refunds helped margins, and the company closed its $950 million Biocare acquisition on June 24, 2026.

How the business did

  • Nine-month net revenue was $5,511 million, also up 8 percent. For the quarter, Life Sciences and Diagnostics Markets grew 11 percent, Agilent CrossLab 6 percent and Applied Markets 7 percent. Pharmaceutical demand was strong, while the academia and government market declined in Life Sciences and Diagnostics Markets.
  • Gross margin (the share of revenue left after the direct cost of products and services) rose to 55.5 percent from 51.1 percent. Operating margin was 23.6 percent versus 20.7 percent, and income from operations was $444 million versus $360 million. Drivers were higher volume, tariff refunds, price increases and lower restructuring expense, partly offset by wage increases and higher variable pay. The tariff refunds added approximately 1 percentage point to operating margin.
  • Cash from operations was $1,064 million for nine months versus $1,014 million a year earlier. Cash and cash equivalents were $1,758 million. In the quarter the company paid $72 million in dividends and repurchased shares for $78 million, leaving approximately $1,654 million of repurchase authorization.
  • Inventory days on hand were 120 days versus 107 days a year earlier, which the filing attributes to strategic purchases to reduce tariff-related risk. The company also issued $600 million of 4.90 percent senior notes due January 15, 2032.

What management is watching

  • Management says customer capital budget availability has "largely normalized" after an extended period of constrained spending, and it remains optimistic about long-term growth. The filing gives no numeric revenue or earnings outlook.
  • Tariffs and the Middle East conflict remain "dynamic." Management says supply chain changes, targeted pricing and cost efficiency offset the cost impact. Further IEEPA tariff refunds are uncertain, and any recovery will be recognized only when it is realized or realizable.
  • Capital expenditures are expected to be approximately $450 million for the year, mainly for expanding advanced therapeutics manufacturing in Frederick, Colorado.
  • A new restructuring plan, with $15 million recorded this quarter, is expected to cut annual costs by approximately $30 million to $35 million. It should be substantially complete by the first quarter of fiscal year 2027.

New or changed risks

  • Tariffs and court rulings on their legality could change purchasing behavior and global trade relationships. Compliance and mitigation costs could reduce operating margin.
  • Geopolitical instability, including conflicts in the Middle East, and evolving trade rules could restrict shipments or the sourcing of components, raise costs and disrupt supply chains.
  • As of July 31, 2026, the company had approximately $3.9 billion in outstanding indebtedness, all in unsecured senior notes. The filing warns that debt could limit cash available for other uses and reduce flexibility.
  • Integrating acquired businesses can be difficult and costly, and expected synergies may not arrive on schedule. This is relevant after the Biocare purchase.

Follow A in Kortex

The Kortex app shows A's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.